Nasdaq Sage News Today

Sage Therapeutics (NASDAQ:SAGE – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $29.00 to $28.00 in a report published on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the stock. […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target decreased by analysts at Royal Bank of Canada from $26.00 to $15.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective decreased by stock analysts at Truist Financial from $22.00 to $18.00 in a report released on Friday, Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 31.48% from the stock’s […]

StockNews.com upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. Several other analysts also recently commented on SAGE. Truist Financial lowered their price objective on Sage Therapeutics from $22.00 to $18.00 and set a hold rating for the company […]

Sage Therapeutics (NASDAQ:SAGE – Free Report) had its target price decreased by Truist Financial from $22.00 to $18.00 in a research report sent to investors on Friday, Benzinga reports. Truist Financial currently has a hold rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on SAGE. Canaccord Genuity Group decreased their price […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target cut by investment analysts at Canaccord Genuity Group from $21.00 to $17.00 in a report issued on Friday, Benzinga reports. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 25.18% from […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target reduced by equities researchers at Mizuho from $20.00 to $18.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 32.06% from […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target lowered by equities researchers at Mizuho from $20.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its target price dropped by investment analysts at HC Wainwright from $28.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 82.08% from the […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link. Sage Therapeutics (NASDAQ:SAGE – […]